Nektar Therapeutics Announces Second Quarter 2026 Financial Results
Nektar reported Q2 revenue of $10.1 million, down from $11.2 million a year ago, with a net loss of $40.6 million or $1.23 per share. The company's financial position strengthened significantly, with cash and investments rising to $1.02 billion from $245.8 million at year-end 2025, extending its cash runway into Q3 2028. The company initiated the first Phase 3 ZENITH AD trials for its lead program rezpegaldesleukin in atopic dermatitis in July, with plans to start a registrational study in alopecia areata in early 2027.
Key figures
- Revenue
- 10100000
- Revenue Yoy
- -9.8%
- Ga expense
- 12800000
- Rd expense
- 39100000
- Cash runway
- Q3 2028
- Offering proceeds
- 373800000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.